Elisha M Wachman1, Marie J Hayes2, Barry M Lester3, Norma Terrin4, Mark S Brown5, David A Nielsen6, Jonathan M Davis7. 1. Pediatrics, Boston Medical Center, Boston, MA. Electronic address: Elisha.Wachman@bmc.org. 2. Psychology, Graduate School of Biomedical Sciences and Engineering, University of Maine, Orono, ME. 3. Center for the Study of Children at Risk, Alpert Medical School of Brown University and Women and Infant's Hospital, Providence, RI. 4. Tufts Clinical and Translational Science Institute, Tufts University, Boston, MA; Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA. 5. Pediatrics, Eastern Maine Medical Center, Bangor, ME. 6. Menninger Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston, TX. 7. Tufts Clinical and Translational Science Institute, Tufts University, Boston, MA; Pediatrics, The Floating Hospital for Children at Tufts Medical Center, Boston, MA.
Abstract
OBJECTIVE: Neonatal abstinence syndrome (NAS) from in utero opioid exposure is highly variable with genetic factors appearing to play an important role. Epigenetic changes in cytosine:guanine (CpG) dinucleotide methylation can occur after drug exposure and may help to explain NAS variability. We correlated DNA methylation levels in the mu-opioid receptor (OPRM1) promoter in opioid-exposed infants with NAS outcomes. STUDY DESIGN: DNA samples from cord blood or saliva were analyzed for 86 infants who were being treated for NAS according to institutional protocol. Methylation levels at 16 OPRM1 CpG sites were determined and correlated with NAS outcome measures, including need for treatment, treatment with ≥ 2 medications, and length of hospital stay. We adjusted for covariates and multiple genetic testing. RESULTS: Sixty-five percent of infants required treatment for NAS, and 24% required ≥ 2 medications. Hypermethylation of the OPRM1 promoter was measured at the -10 CpG in treated vs nontreated infants (adjusted difference δ = 3.2% [95% CI, 0.3-6.0%], P = .03; nonsignificant after multiple testing correction). There was hypermethylation at the -14 (δ = 4.9% [95% CI, 1.8%-8.1%], P = .003), -10 (δ = 5.0% [95% CI, 2.3-7.7%], P = .0005), and +84 (δ = 3.5% [95% CI, 0.6-6.4], P = .02) CpG sites in infants requiring ≥ 2 medications, which remained significant for -14 and -10 after multiple testing correction. CONCLUSIONS: Increased methylation within the OPRM1 promoter is associated with worse NAS outcomes, consistent with gene silencing.
OBJECTIVE:Neonatal abstinence syndrome (NAS) from in utero opioid exposure is highly variable with genetic factors appearing to play an important role. Epigenetic changes in cytosine:guanine (CpG) dinucleotide methylation can occur after drug exposure and may help to explain NAS variability. We correlated DNA methylation levels in the mu-opioid receptor (OPRM1) promoter in opioid-exposed infants with NAS outcomes. STUDY DESIGN: DNA samples from cord blood or saliva were analyzed for 86 infants who were being treated for NAS according to institutional protocol. Methylation levels at 16 OPRM1 CpG sites were determined and correlated with NAS outcome measures, including need for treatment, treatment with ≥ 2 medications, and length of hospital stay. We adjusted for covariates and multiple genetic testing. RESULTS: Sixty-five percent of infants required treatment for NAS, and 24% required ≥ 2 medications. Hypermethylation of the OPRM1 promoter was measured at the -10 CpG in treated vs nontreated infants (adjusted difference δ = 3.2% [95% CI, 0.3-6.0%], P = .03; nonsignificant after multiple testing correction). There was hypermethylation at the -14 (δ = 4.9% [95% CI, 1.8%-8.1%], P = .003), -10 (δ = 5.0% [95% CI, 2.3-7.7%], P = .0005), and +84 (δ = 3.5% [95% CI, 0.6-6.4], P = .02) CpG sites in infants requiring ≥ 2 medications, which remained significant for -14 and -10 after multiple testing correction. CONCLUSIONS: Increased methylation within the OPRM1 promoter is associated with worse NAS outcomes, consistent with gene silencing.
Authors: David A Nielsen; Sara Hamon; Vadim Yuferov; Colin Jackson; Ann Ho; Jurg Ott; Mary Jeanne Kreek Journal: Hum Genet Date: 2010-03-18 Impact factor: 4.132
Authors: Neil S Seligman; Nicole Salva; Edward J Hayes; Kevin C Dysart; Edward C Pequignot; Jason K Baxter Journal: Am J Obstet Gynecol Date: 2008-10 Impact factor: 8.661
Authors: Riju Ray; Kosha Ruparel; Andrew Newberg; E Paul Wileyto; James W Loughead; Chaitanya Divgi; Julie A Blendy; Jean Logan; Jon-Kar Zubieta; Caryn Lerman Journal: Proc Natl Acad Sci U S A Date: 2011-05-16 Impact factor: 11.205
Authors: Gregory A Michelotti; D Marshall Brinkley; Daniel P Morris; Michael P Smith; Raphael J Louie; Debra A Schwinn Journal: FASEB J Date: 2007-03-23 Impact factor: 5.191
Authors: Amalia S Lehmann; David M Haas; Catherine L McCormick; Todd C Skaar; Jamie L Renbarger Journal: Am J Obstet Gynecol Date: 2011-02-16 Impact factor: 8.661
Authors: David A Nielsen; Vadim Yuferov; Sara Hamon; Colin Jackson; Ann Ho; Jurg Ott; Mary Jeanne Kreek Journal: Neuropsychopharmacology Date: 2008-07-23 Impact factor: 7.853
Authors: Irma Convertino; Alice Capogrosso Sansone; Alessandra Marino; Maria T Galiulo; Stefania Mantarro; Luca Antonioli; Matteo Fornai; Corrado Blandizzi; Marco Tuccori Journal: Drug Saf Date: 2016-10 Impact factor: 5.606
Authors: Fair M Vassoler; Michelle L Oranges; Anika M Toorie; Elizabeth M Byrnes Journal: Pharmacol Biochem Behav Date: 2018-07-26 Impact factor: 3.533
Authors: Nicole A Heller; Beth A Logan; Deborah G Morrison; Jonathan A Paul; Mark S Brown; Marie J Hayes Journal: Dev Psychobiol Date: 2017-05-31 Impact factor: 3.038
Authors: Elisha M Wachman; Marie J Hayes; Richard Sherva; Mark S Brown; Jonathan M Davis; Lindsay A Farrer; David A Nielsen Journal: Drug Alcohol Depend Date: 2015-07-08 Impact factor: 4.492
Authors: Tess Flannery; Jonathan M Davis; Adam J Czynski; Lynne M Dansereau; Erica L Oliveira; Samantha A Camardo; Barry M Lester Journal: J Pediatr Date: 2020-08-14 Impact factor: 4.406